The projection of portfolio receipts between $2.6 billion and $2.7 billion for FY24 by Royalty Pharma is a positive signal for investors, indicating expected revenue growth. This forecast is likely to be viewed favorably by the market, potentially leading to an increase in investor confidence and a positive impact on the stock price in the short term.